---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacodynamics"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacodynamics. Topics: Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks; Serum tryptase depletion in the phase 2 CSU trial; Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis; Tryptase recovery during the 24-week follow-up period of the phase 2 CSU trial; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).”
> “Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).”
> “Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.”
> “Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).”
> “The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.”
> “All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.2-2"></a>

### Serum tryptase depletion in the phase 2 CSU trial

> “In a Phase 2 study in patients with H1-antihistamine-refractory CSU (NCT05368285), barzolvolimab, a highly potent, first-in-class anti-KIT monoclonal antibody, demonstrated rapid, profound, and durable depletion of serum tryptase, with corresponding improvements in clinical symptoms”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis

> “Mean baseline serum tryptase levels were compared between pooled barzolvolimab studies in patients with CSU (n=239) and healthy participants (n=94)”
> “Exploratory, post hoc efficacy analyses from the Phase 2, double-blind, placebo-controlled study (NCT05368285) assessed the association of baseline serum tryptase with baseline disease severity and response to barzolvolimab at Week 12 and Week 52 in patients with H1-antihistamine-refractory CSU”
> “Patients with CSU had higher mean (range) baseline serum tryptase than HV (5.8 [<1-36.2] vs 4.2 [1.1-21.2] ng/mL)”
> “Baseline serum tryptase levels were higher among patients with CSU than healthy participants, consistent with increased MC burden or activation as a driver of disease”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”
> “Barzolvolimab demonstrated clinical benefits for patients with CSU regardless of their baseline serum tryptase levels”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

| Timepoint | Response definition | Area under the ROC curve for baseline serum tryptase |
| --- | --- | --- |
| Week 12 | UAS7 = 0 | “0.49” |
| Week 12 | UAS7 ≤6 | “0.53” |
| Week 52 | UAS7 = 0 | “0.51” |
| Week 52 | UAS7 ≤6 | “0.56” |

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Tryptase recovery during the 24-week follow-up period of the phase 2 CSU trial

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Following a 52-week total treatment period, patients entered a 24-week follow-up period”
> “Analyses on barzolvolimab concentrations versus urticaria activity scores and circulating tryptase, a soluble mast cell marker, were conducted.”
> “Tryptase recovers towards range of healthy subjects by week 76 indicating normal mast cell numbers”
> “Despite gradual decreasing concentration of barzolvolimab and tryptase recovery, mean UAS7 scores remained low”
> “Sustained off-treatment efficacy was observed despite barzolvolimab clearance and normalization of tryptase”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses

> “A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.”
> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).”
> “Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.”
> “At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.”
> “At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).”
> “No significant change in tryptase was observed in the placebo group.”
> “We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.”
> “Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.2-6"></a>

### Serum tryptase in healthy volunteers: single subcutaneous doses

> “A randomized, double-blind, placebo-controlled, Phase 1 study designed to evaluate the safety of single ascending doses of the subcutaneous formulation of CDX-0159 has been conducted in healthy volunteers.”
> “Importantly, subcutaneous delivery of CDX-0159 resulted in dose-dependent, rapid and sustained decreases in serum tryptase compared with placebo and achieved sufficient exposure to produce tryptase suppression levels comparable with the levels that generated impressive clinical activity observed in the Phase 1 chronic inducible urticaria IV study.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.6.2-7"></a>

### Cold urticaria and symptomatic dermographism: skin mast cell depletion, tryptase, and SCF after one 3 mg/kg intravenous dose

> “This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up.”
> “Treatment resulted in significant depletion of skin MCs, decreased tryptase (<limit of detection), and increased soluble SCF through Week 12.”
> “The concomitant increase in circulating SCF as a result of KIT blockade by barzolvolimab is indicative of KIT engagement in tissues (Figure 1B,C).”
> “Skin MC reduction was observed and independently assessed by staining for tryptase (89% decrease at Week 12) and CD117 (KIT; 87% decrease at Week 12; Figure 1G,H).”
> “The kinetics of serum tryptase reduction correlated with that of CD117-positive and tryptase-positive skin MC numbers, demonstrating circulating tryptase is a surrogate marker for skin MC number (Figure S2).”
> “There was no change from baseline in epidermal CD117 (KIT+) melanocytes at any timepoint (Figure 1F).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.2-8"></a>

### Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36

> “Patients with two forms of CIndU (SD; n = 10 and ColdU; n = 10) received a single 3 mg/kg intravenous dose of barzolvolimab.”
> “As early as 1 week following drug administration, MC numbers rapidly decreased, reaching approximately 90% reduction after 8 weeks and with similar kinetics as reductions in serum tryptase and clinical symptoms (Figure S3).”
> “MCs only recovered partially 36 weeks after dosing (31% for tryptase and 38% for CD117 from baseline), suggesting that MCs can repopulate skin, albeit very slowly.”
> “In contrast to IHC data, MC transcripts completely recovered by Week 36 (Figure 2A) and the kinetics closely mirrored that of clinical symptoms and serum tryptase (Figure 2B–D).”
> “Our data demonstrate that KIT‐dependent MC reduction is fully reversible and that mature and reactive MCs repopulate skin from MC progenitors within several weeks following their depletion.”

Source: [Alvarado et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12862557/)

> “A single dose of barzolvolimab led to marked decreases in tryptase and in skin mast cells.”
> “This confirmed that serum tryptase level is a robust pharmacodynamic biomarker for assessing mast cell burden and clinical activity in inducible urticaria and potentially in other diseases with mast cell driven involvement.”
> “Serum tryptase exhibits a similar rate of recovery as clinical symptoms, while skin mast cells return at a slower rate.”
> “Tissue KIT signaling, as approximated by SCF levels, was rapidly inhibited after dose administration and fully reactivated approximately 18 weeks after dosing.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.6.2-9"></a>

### Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2

> “This randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE.”
> “65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “Peak mast cell counts (CD117 positive cells) per high power field (hpf) at baseline were 50.3 in the placebo arm and 55.4 in the barzolvolimab 300mg Q4W arm.”
> “At Week 12 the absolute change from baseline was -2.7 for placebo compared to -36.0 for barzolvolimab [Diff (95%CI): -33.3 (-44.1, -22.6); p=<0.0001)].”
> “Mast cells defined by tryptase staining also showed profound decreases at week 12 in barzolvolimab treated patients with sustained and deepening decreases observed at Week 28.”
> “Despite profound mast cell depletion, no definitive evidence of clinical improvement in EoE symptoms, as measured by the Dysphagia Symptom Questionnaire (DSQ) (p=0.33), or endoscopic scoring of EoE-related inflammation & fibrosis (EREFS) (p=0.95) were observed compared to placebo.”
> “There was also no difference observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.6.2-10"></a>

### Prurigo nodularis: serum tryptase with a 450 mg loading dose, phase 2

> “This Phase 2 randomized, double-blind, placebo-controlled, parallel group study evaluated barzolvolimab compared to placebo in patients with moderate to severe PN who had inadequate response to prescription topical medications, or for whom topical medications were medically inadvisable.”
> “140 patients were randomly assigned to receive barzolvolimab 150mgQ4W after an initial loading dose of 450mg, 300mgQ4W after an initial loading dose of 450mg, or placebo during a 24-week Treatment Phase.”
> “The study did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.”
> “Rapid and profound suppression of circulating tryptase, indicative of systemic mast cell depletion, was observed.”
> “The addition of the 450mg loading dose led to early, profound tryptase reduction that was sustained over the duration of the treatment period.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="topic-2.1.2.6.2-11"></a>

### Prurigo nodularis: serum tryptase and plasma SCF after a single intravenous dose

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Serum tryptase levels declined rapidly in a dose-dependent manner in barzolvolimab-treated participants”
> “Most 3.0 mg/kg barzolvolimab-treated participants experienced tryptase suppression below the levels of assay detection by week 8, with plasma stem cell factor increases mirroring tryptase suppression kinetics”
> “Greater efficacy observed with the 3.0 mg/kg dose suggests that profound and sustained tryptase reduction may be needed to maximize clinical benefit in PN.”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.6.2-12"></a>

### Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color

> “To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.”
> “CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.”
> “Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).”
> “In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).”
> “Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

Additional sources: [Moñino-Romero et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439351/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
